Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Acute biliary events during anti-tuberculosis treatment: hospital case series and a nationwide cohort study

BMC Infectious DiseasesBMC series – open, inclusive and trusted201818:64

https://doi.org/10.1186/s12879-018-2966-3

  • Received: 4 July 2017
  • Accepted: 17 January 2018
  • Published:
Open Peer Review reports

Abstract

Background

Tuberculosis (TB) remains one of the major infectious diseases worldwide. Adverse reactions are common during TB treatment. Few reports, however, are available on treatment-related acute biliary events (ABEs), such as cholelithiasis, biliary obstruction, acute cholecystitis, and cholangitis.

Methods

We first report four pulmonary TB patients who developed ABEs during anti-TB treatment. Abdominal sonography revealed multiple gall stones with dilated intrahepatic ducts in three patients and cholecystitis in one patient. To investigate the incidence of and risk factors for ABEs during anti-TB treatment, we subsequently conducted a nationwide cohort study using the National Health Insurance Research Database of Taiwan.

Results

A total of 159,566 pulmonary TB patients were identified from the database between 1996 and 2010, and among them, 195 (0.12%) developed ABEs within 180 days after beginning anti-TB treatment. Logistic regression analysis revealed that the risk factors associated with ABEs are older age (relative risk [RR]: 1.32 [1.21–1.44] per 10-year increment) and diabetes mellitus (RR: 1.59 [1.19–2.13]).

Conclusions

Although infrequently encountered, ABEs should be considered among patients with TB who experience abdominal discomfort with hyperbilirubinemia, especially patients who have older age or diabetes.

Keywords

  • Tuberculosis
  • Biliary event
  • Cholelithiasis
  • Cholecystitis
  • Cholangitis
  • National Health Insurance Research Database

Background

Tuberculosis (TB) remains one of the most deadly infectious diseases worldwide [1]. In 2015, approximately 10.4 million new cases of TB were diagnosed globally. Despite a decrease in the mortality rate in 2015 from 2000, TB caused approximately 1.8 million deaths in 2015 [1]. Although effective anti-TB drugs are readily available, the treatment of TB is not always successful because treatment-emergent adverse events—such as hepatotoxicity, peripheral neuropathy, gastrointestinal upset, hyperuricemia, optic neuritis, and cutaneous reactions [2]—often lead to treatment interruption and further dissemination of the TB bacilli.

Hepatotoxicity is the most common adverse event associated with TB treatment, with an incidence rate between 10.2% and 18.9% in Taiwan, and it is potentially life-threatening [36]. The risk of drug-induced liver injury during anti-TB treatment ranges from 5% to 33% according to the American Thoracic Society [7]. Clinical presentations may include low-grade fever, general malaise, poor appetite, nausea, vomiting, abdominal distension, icteric conjunctiva, and elevated serum aminotransferases and bilirubin levels. These symptoms and signs are typically indistinguishable from those of acute biliary events (ABEs) such as cholelithiasis, biliary obstruction, acute cholecystitis, and cholangitis. Delayed or incorrect diagnosis of ABEs may cause unnecessary anti-TB treatment interruption, or if left untreated, may lead to intra-abdominal complications, such as acute pancreatitis, sepsis, or perforation [8]. However, the association between ABEs and anti-TB treatment has not been elucidated thus far. Therefore, in this paper, we first report four cases of ABEs during anti-TB treatment, and subsequently, we investigate the incidence rate and risk factors of ABEs during anti-TB treatment in a nationwide TB cohort.

Methods

This study consisted of two parts. In the first part (case series), we obtained the clinical presentations and treatment histories of patients with pulmonary TB who developed ABEs during anti-TB treatment at the National Taiwan University Hospital and its Hsinchu Branch between 2010 and 2015. In the second part (nationwide cohort), we conducted a nationwide cohort study using claims data from the National Health Insurance Research Database (NHIRD) of Taiwan to evaluate the incidence rate of ABEs during anti-TB treatment and identify risk factors for ABEs.

Ethics statement

The Institutional Review Board of the National Taiwan University Hospital and its Hsinchu Branch approved the study (NTUH REC: 201,309,064 W; NTUH-HC REC: 105–023-E). Due to the study’s retrospective design, inform consent was deemed unnecessary.

Identification of ABE cases in the hospital-based cohort (case series)

Definition of ABEs

An adverse event was considered an ABE if it met both of the following criteria: (1) abnormal liver function during anti-TB treatment; and (2) diagnosis with image confirmation, such as abdominal computed tomography or sonography.

Case selection

Between 2010 and 2015, a total of 3686 patients with pulmonary TB were treated at the National Taiwan University Hospital (n = 2704) and its Hsinchu Branch (n = 982). Among them, 2879 (78.1%) had culture-confirmed pulmonary TB. Liver function (aspartate aminotransferase [AST], alanine aminotransferase [ALT], and total bilirubin) was evaluated at baseline and at least once during anti-TB treatment in 3675 (99.7%) patients, and significant elevation in AST and ALT levels was noted in 416 (11.3% of 3675) patients. The medical records of these 416 patients were reviewed to determine whether ABE was responsible for abnormal liver function in these patients. The diagnosis of ABE was also confirmed using imaging modalities.

Analysis of nationwide cohort

Definition of ABEs

An adverse event was considered an ABE if it met both of the following criteria: (1) diagnosis of cholelithiasis (ICD-9-CM code 574), acute cholecystitis (ICD-9-CM code 575.0–575.2), cholangitis (ICD-9-CM code 576.1), or obstruction of biliary tract (ICD-9-CM code 576.2); and (2) the patient had received at least one of the examinations and management therapies listed in Table 1. The primary outcome was ABEs that occurred within 180 days after commencement of anti-TB treatment.
Table 1

Examinations and management of acute biliary events

 

Examination or Management

NHIRD code

Non-invasive Study

Cholescintigraphy

26040B

Oral cholecystography

33020B

Intravenous choledochocystography

33021B

Invasive Study

Transduodenal choledochoscopy

28032B

Percutaneous transhepatic choledochoscopy

28036B

Endoscopic retrograde cholangiopancreatography

33024B

Percutaneous transhepatic cholangiography

33025B

Drainage

Fiber choledochoscopy, percutaneous via T-tube or other tract

28034B

T-tube cholecystography

33022B

Percutaneous transhepatic cholangiography-drainage

33026B

Percutaneous gall bladder drainage

33106B

Endoscopic retrograde biliary drainage

56020B

Endoscopic nasobiliary drainage

56021B

Choledochoscopy and choledochotomy

56034B

Choledochotomy with T-tube drainage

75208B

Choledocholithotomy with T-tube drainage

75209B

Stone Removal

Fiber choledochoscopy, percutaneous via T-tube or other tract, with removal of stones

28008B

Fiber choledochoscopy, intraoperative, with removal of stones

28035B

PTCD-stone removal

33083B

Choledocholithotomy (transduodenal)

75202B

Operation

 Traditional

Fiber choledochoscopy, intraoperative

28007B

Operative cholangiography

33023B

Cholecystostomy

75201B

Cholecystectomy

75203B

Choledochojejunostomy

75204B

Cholecystoenterostomy

75205B

 Laparoscopic

Laparoscopic cholecystectomy

75215B

Laparoscopic choledocholithotripsy

75218B

Case selection

We identified patients in the NHIRD who had been diagnosed with pulmonary TB from 1996 to 2010 (Fig. 1). Active TB was defined by the following criteria: (1) at least two outpatient records or one inpatient record with a compatible diagnosis; (2) one prescription of at least three anti-TB medications; and (3) receiving two or more anti-TB medications simultaneously over a period of 120 days within a 180-day period [9]. Patients who were diagnosed with nontuberculous mycobacterial infection (ICD-9-CM code 031) during the last 60 days of anti-TB treatment were excluded. Patients who met any of the ABE diagnostic criteria before anti-TB treatment were also excluded. Date of treatment completion was defined as the last date on which two or more anti-TB drugs were taken simultaneously without receiving any anti-TB medication in the subsequent 60 days.
Fig. 1
Fig. 1

Flowchart of selection of pulmonary TB cases in the nationwide cohort

Comorbidity and income status

Comorbid conditions—comprising diabetes mellitus (DM), chronic obstructive pulmonary disease (COPD), malignancy, end-stage renal disease, connective tissue disease, acquired immunodeficiency syndrome, liver cirrhosis, transplantation, pneumoconiosis, and low-income status—at the time TB diagnosis were identified by using previously published definitions [9, 10].

Statistical analyses

Intergroup differences were assessed by using independent-sample t tests for continuous variables and chi-square or Fisher exact tests for categorical variables. The risk factors for ABEs in patients with pulmonary TB were evaluated using logistic regression analyses. Only variables with a two-sided p < 0.05 were included in the final model. All analyses were performed using IBM SPSS Statistics Version 22 (IBM Corp., Armonk, NY, USA).

Results

Case series in the hospital cohort

Case 1

A male patient in his 80s with comorbid, medically controlled hypertension and DM received standard four-drug anti-TB treatment (isoniazid, rifampin, ethambutol, and pyrazinamide) for his smear-positive, culture-confirmed pulmonary TB. He experienced fever and chills after one week of treatment. Laboratory examinations showed elevated AST (212 IU/L) and ALT (375 IU/L) and direct-type hyperbilirubinemia (total bilirubin: 2.81 mg/dL; direct bilirubin: 2.57 mg/dL). Abdominal sonography revealed the presence of multiple gall stones and dilated intrahepatic ducts. Anti-TB treatment was discontinued and ceftazidime was prescribed. One month later, the patient underwent a laparoscopic cholecystectomy procedure, followed by the resumption of anti-TB treatment. Thereafter, ABEs were not noted.

Case 2

A male patient in his 50s with comorbid, medically controlled DM and COPD was diagnosed with pulmonary TB based on a histology report of a transbronchial lung biopsy and a mycobacterial culture of bronchial washing sample. The first 3 weeks of four-drug anti-TB treatment were uneventful, but after 4 weeks of treatment, he experienced nausea and vomiting. Laboratory tests revealed elevated transaminase (AST: 144 IU/L and ALT: 358 IU/L). A minimal amount of ascites in the right subdiaphragmatic area was observed using abdominal sonography. A small amount of ascites was also observed in the perigallbladder, right anterior pararenal, and pelvic space one week later using abdominal computed tomography. The patient was diagnosed with acute cholecystitis. Anti-TB treatment was interrupted and cefmetazole was administered. After his adverse reactions had resolved, anti-TB treatment was successfully resumed.

Case 3

A man in his 50s with comorbid hypertension and COPD, which were under irregular medical control, was diagnosed with smear-positive, culture-confirmed pulmonary TB. Two weeks prior to the commencement of standard anti-TB treatment, he had pneumonia with respiratory failure and septic shock. Laboratory tests demonstrated elevated transaminase levels, but normal total and direct bilirubin (AST: 144 IU/L; ALT: 358 IU/L; and total bilirubin: 0.52 mg/dL). Neither gallbladder stones nor bile duct stones were identified using computed tomography (slide thickness: 5 mm; interval: 1.2 mm). The patient was treated with courses of antibiotics, which improved his respiratory condition, hemodynamic condition, and aminotransferase levels (AST: 51 IU/L; ALT: 23 IU/L). The standard four-drug anti-TB treatment was started subsequently. However, after receiving anti-TB treatment for two weeks, his bilirubin level was increased, with a mild elevation in transaminase level (AST: 77 IU/L; ALT: 49 IU/L; total bilirubin: 4.57 mg/dL; and direct bilirubin: 3.84 mg/dL). Anti-TB treatment was halted. Multiple cholelithiasis with a dilated intrahepatic duct was diagnosed using abdominal sonography. Soon after the patient underwent the sonography procedure, he experienced another episode of pneumonia with septic shock and respiratory failure. Although bilirubin and transaminase both improved after interruption of anti-TB treatment for 10 days (AST: 61 IU/L; ALT: 38 IU/L; total bilirubin: 1.72 mg/dL; and direct bilirubin: 1.37 mg/dL), the general condition of the patient deteriorated gradually. The patient died of refractory septic shock.

Case 4

A previously healthy male patient in his 20s was diagnosed with smear-positive, culture-confirmed pulmonary TB and TB pleurisy. No cholelithiasis was noted in abdominal sonographs obtained 2 years prior to the diagnosis of TB. The standard four-drug anti-TB treatment improved his TB clinical symptoms, including fever, chest pain, and left pleural effusion; however, abnormal liver function was noted (AST: 303 IU/L; ALT: 499 IU/L; and total bilirubin: 0.56 mg/dL) after 6 weeks of treatment, which resolved (ASL: 26 IU/L; ALT: 34 IU/L; total bilirubin: 0.1 mg/dL) after the interruption of anti-TB treatment. In the 18th week, anti-TB treatment with isoniazid, rifampin, and ethambutol was resumed. However, the patient experienced acute abdominal cramping pain in the following week. His aminotransferase and bilirubin level did not increase (AST: 22 IU/L; ALT: 17 IU/L; and total bilirubin: 0.57 mg/dL). Multiple small cholelithiases were discovered using abdominal sonography. Rechallenge with anti-TB treatment was complicated by recurrent abdominal cramping pain immediately after taking the anti-TB drugs. Because gastroenterologists suggested a possible diagnosis of intermittent biliary obstruction due to a passing stone, he received conservative management. The anti-TB treatment was successfully completed in the ninth month after TB diagnosis.

The demographic characteristics and clinical course of these four patients are summarized in Table 2.
Table 2

Characteristics and clinical course of the cases of acute biliary events

 

Case 1

Case 2

Case 3

Case 4

Age (decade of life)

9th

6th

6th

3rd

Sex

male

male

male

male

Co-morbidity

DM

DM, COPD

HTN, COPD

Nil

Anti-TB regimen before ABE

HREZ

HREZ

HREZ

HRE

Presenting symptoms

Fever/Chills

Nausea/Vomiting

Fever

Abdominal pain

Peak ALT level (U/L)a

375

303

16

499

Peak AST level (U/L)b

212

223

98

303

Peak total bilirubin level (mg/dL)c

2.81

1.53

1.69

0.57

Diagnosis of ABE

Cholecystitis

Cholecystitis

Cholelithiasis with biliary obstruction

Cholelithiasis with biliary obstruction

Onset of ABE

1 week later

4 weeks later

2 weeks later

18 weeks later

Treatment of ABE

LC

Antibiotics

Antibiotics

Antibiotics

ABE Acute biliary event, ALT Alanine aminotransferase, AST Aspartate aminotransferase, COPD Chronic obstructive pulmonary disease, DM Diabetes mellitus, E Ethambutol, H Isoniazid, HTN Hypertension, LC laparoscopic cholecystectomy, R Rifampin, TB Tuberculosis, Z Pyrazinamide

anormal range of ALT: 2–32 U/L

bnormal range of AST: 10–30 U/L

cnormal range of total bilirubin: 0.2–1.2 mg/dL

NHIRD cohort

From the beneficiaries listed in the NHIRD between 1996 and 2010, a total of 682,875 cases with diagnosis of pulmonary TB were identified (Fig. 1). A total of 159,566 cases that met the diagnostic criteria for pulmonary TB were included for further analysis. Subsequent analysis identified 195 (0.12%) patients who developed ABEs within the initial 180 days of treatment. The patients who did not develop ABEs comprised the non-ABE group. The clinical characteristics of the ABE and non-ABE groups—their age, sex, and underlying comorbidities—are summarized in Table 3. The mean age of the patients in the ABE and non-ABE groups was 66.2 ± 13.5 years and 56.6 ± 19.7 years, respectively (p < 0.001). Men accounted for 67.7% of the ABE group and 68.6% of the non-ABE group (p = 0.075). Of the underlying comorbidities and income condition, a significant difference was only obtained between the ABE and non-ABE groups regarding DM prevalence (p < 0.001). The duration and type of anti-TB treatment were similar between the ABE and non-ABE groups, except for rifamycin prescription during the initial 60 and 180 days after TB diagnosis and isoniazid prescription during the initial 180 days.
Table 3

Characteristics of patients with and without acute biliary events

 

ABE group (n = 195)

Non-ABE group (n = 159,371)

Age (years)a*

66.2 ± 13.5

56.6 ± 19.7

Maleb

132 (67.7)

109,399 (68.6)

Tuberculosis diagnostic yearb

 1996–2000

60 (30.8)

48,844 (30.6)

 2001–2005

73 (37.4)

59,424 (37.3)

 2006–2010

62 (31.8)

51,103 (32.1)

Co-morbidity (%)

 Diabetes mellitusb*

63 (37.4)

38,075 (23.9)

 Chronic obstructive pulmonary diseaseb

10 (5.1)

7918 (5.0)

 Malignancyb

12 (6.2)

6712 (4.2)

 End-stage renal diseasec

2 (1.0)

1998 (1.3)

 Connective tissue diseasec

0 (0.0)

1151 (0.7)

 Acquired immunodeficiency syndromec

1 (0.5)

562 (0.4)

 Liver cirrhosisc

1 (0.5)

323 (0.2)

 Transplantationc*

1 (0.5)

137 (0.1)

 Pneumoconiosisc

0 (0)

85 (0.1)

Low incomeb

5 (2.6)

4830 (3.0)

Total duration of anti-TB treatment

266.9 ± 99.7

260.4 ± 105.8

 Intensive phase (initial 60 days)a

  No. of days covered by isoniazida

47.7 ± 18.6

50.0 ± 11.2

  No. of days covered by rifamycina*

48.9 ± 13.4

51.7 ± 11.2

  No. of days covered by ethambutola

51.2 ± 11.4

50.8 ± 13.1

  No. of days covered by pyrazinamidea

39.9 ± 21.3

42.5 ± 20.4

 Initial 180 days

  No. of days covered by isoniazida*

134.4 ± 52.2

142.4 ± 53.4

  No. of days covered by rifamycina*

140.1 ± 37.9

152.5 ± 32.8

  No. of days covered by ethambutola

145.2 ± 35.6

141.9 ± 42.2

  No. of days covered by pyrazinamidea

67.8 ± 44.9

69.3 ± 45.8

Data are presented as number (%) or mean ± standard deviation

aCompared using an independent-sample t test

bCompared using a chi-square test

cCompared using a Fisher exact test

*p < 0.05 for the comparison between the ABE and non-ABE groups

The onset of ABEs was evenly distributed within the 180-day period (Fig. 2). The median number of days of onset was 76 days (IQR: 76–133) after initiation of anti-TB treatment. Seventy-two (36.9%) events occurred within the first 60 days of anti-TB treatment, 65 (33.3%) within the next 60 days, and the remaining 58 (29.7%) within the final 60 days. Among the 195 patients, 132 (67.7%) received surgical intervention, which was either a traditional operation (n = 72) or laparoscopic surgery (n = 60) (Table 4). Twenty-four (12.3%) received nonsurgical stone removal, and 66 (33.3%) drainage.
Fig. 2
Fig. 2

Time of onset of acute biliary events

Table 4

Management and intervention for acute biliary events in the nationwide cohort

 

ABE Group (n = 195)

Non-invasive study (excluding abdominal sonography)

5 (2.6%)

Invasive study

63 (33.3%)

Drainage

66 (33.8%)

Stone removal

24 (12.3%)

Operation

132 (67.7%)

 Traditional operation

72 (36.9%)

 Laparoscopic operation

60 (30.8%)

Risk factors associated with ABEs were assessed using multivariable logistic regression analysis. We discovered that age (p < 0.001; relative risk [RR]: 1.32 [1.21–1.44] per 10-year increment) and DM (p < 0.001; RR: 1.59 [1.19–2.13]) were significantly associated with occurrence of ABEs.

Discussion

To our knowledge, this was the first study to investigate ABEs during anti-TB treatment. The incidence rate of ABEs during anti-TB treatment in the case study cohort was 0.11% (4/3686), which was similar to the finding in the nationwide cohort (0.12%). ABEs do not appear to onset at a particular time. The risk factors for ABEs are older age and comorbid DM, with the latter occurring in half of the patients in the case series.

Because ethambutol and streptomycin are the only first-line TB therapies that are not associated with hepatotoxicity, abnormal liver function remains common during anti-TB treatment. Transient asymptomatic elevation of aminotransferase levels was observed in 10% to 20% of patients who have received isoniazid [11]. Furthermore, transient asymptomatic hyperbilirubinemia was detected in 0.6% of patients receiving rifampin [2]. The incidence of symptomatic and severe hepatotoxicity varies between different studies, ranging from 5% to 33% [7]. However, the clinical presentations of hepatotoxicity are typically indistinguishable from those of ABEs. Distinguishing hepatotoxicity from ABEs has not been investigated in this field. Therefore, when a patient who is treated for TB presents symptoms of an ABE—right upper quadrant pain, nausea, and vomiting with hyperbilirubinemia— the patient may be misdiagnosed with drug-induced hepatitis by the primary care physician. If the ABE is mild or self-limited, such as a passing stone, the physician may attribute the patient’s recovery to discontinuation of anti-TB treatment, further delaying the diagnosis of an ABE. Because some ABE cases should be managed aggressively with invasive procedures (more than two-thirds in the present nationwide cohort), delayed diagnosis may increase morbidity and mortality [12]. The findings of this study emphasize that although ABEs are not common, increasing awareness of these potential complications and practicing differential diagnosis are crucial for early diagnosis and proper management of ABEs.

From the nationwide cohort in this study, we discovered that older age and comorbid DM are two significant risk factors for ABEs during anti-TB treatment. These findings are similar to those of a previous multicenter study performed in Italy [13], which discovered that older age and DM are both independent risk factors for cholelithiasis. Epidemiological studies on the risk of gallbladder disease among patients with DM have yielded inconsistent results. In a case–control study [14], the prevalence of DM was significantly higher in patients with gallstone than in the control group (11.6% vs. 4.8%, odds ratio 2.55 [1.39–4.67]). In studies demonstrating a positive association between DM and gallbladder disease or gallstones, the risk ratios have been reported to lie in the range 1.68–2.09 [1518]. Other studies, however, have not found an association [19, 20]. The results of a recent meta-analysis suggested that a diagnosis of DM may increase the relative risk of gallbladder disease by 56% [21].

Patients with ABEs during anti-TB treatment may have asymptomatic cholelithiasis before treatment. When treatment begins, isoniazid and rifampin may inhibit the bile salt export pump [22] and accelerate the formation of cholesterol stone [23], with the previous asymptomatic stone used as a nucleus, resulting in a higher risk of ABEs. Cholelithiasis may be caused by either cholesterol gallstones, which are a mixture of cholesterol, bile salt, and phospholipids, or pigmented gallstones. The relative proportion of each component predicts if the mixture of cholesterol, bile salt, and phospholipids forms crystals, micelles, or vesicle micelles [24]. Crystal formation is associated with higher proportion of bile salt. The crystal becomes the nucleus of a cholesterol gallstone. Insulin treatment has been shown to increase the biliary saturation index, resulting in cholesterol precipitation and gallstone formation [25, 26].

Another possible mechanism for the increased risk of an ABE in patients with DM may be decreased gallbladder motility as a result of denervation [27, 28]. The underlying pathogenesis is still unclear. One possibility is fewer cholecystokinin receptors on the gallbladder wall due to diabetic autonomic neuropathy leading to poor response to cholecystokinin stimulation [27]. In addition to impaired cholinergic innervation, cholecystoparesis may result from increased dopaminergic activity [2932].

We discovered that duration of rifamycin use in the ABE group was significantly shorter than that in the non-ABE group. This finding is most likely to be confounded by indication. Among the first-line anti-TB drugs, only rifampin has been reported to be associated with cholestasis, which typically occurs in the first month of treatment [7]. Rifampin inhibits the major bile salt exporter pump and blocks bilirubin uptake [33]. In addition, rifampin competitively affects the clearance of bilirubin from the sinusoidal membrane or canaliculular level in a dose-dependent manner [34, 35]. Therefore, when the bilirubin level increases, primary care physicians tend to discontinue rifamycin treatment first. However, it was impossible to confirm the effect of rifampin on the development of ABEs in this retrospective study. Because it is unethical to treat TB without using rifamycin, a prospective interventional study comparing different doses of rifampin could be used to address this issue.

The present study had some limitations. First, because of the retrospective design of the study, the incidence of ABEs was probably underestimated in the hospital-based cohort because of missing mild and transient events. However, the effect of this underestimation may not be large because serum transaminase and bilirubin assessments in the second, fourth, and eighth weeks of treatment are recommended by TB treatment guidelines in Taiwan [36], and the percentage of follow-up tests performed for liver function in the hospital-based cohort was > 90%. Second, because the NHIRD cohort study was based solely on claims data, ABE incidence may have been underestimated because of noncomprehensive data. Finally, the causal relationships between ABEs, rifampin treatment, and comorbid DM were not addressed. Further prospective studies are necessary to clarify these issues.

Conclusion

Although uncommon, ABEs develop in approximately 0.12% of patients with pulmonary TB receiving anti-TB treatment. Clinicians should be aware of this potential complication of anti-TB treatment and maintain high clinical suspicion for patients with pulmonary TB who experience abdominal discomfort during anti-TB treatment, especially elderly patients and those with DM.

Abbreviations

ABE: 

Acute biliary event

ALT: 

Alanine aminotransferase

AST: 

Aspartate aminotransferase

COPD: 

Chronic obstructive pulmonary disease

DM: 

Diabetes mellitus

NHIRD: 

National Health Insurance Research Database

RR: 

Relative risk

TB: 

Tuberculosis

Declarations

Acknowledgements

The authors thank the National Health Research Institute of Taiwan for providing access to the National Health Insurance Research Database.

Funding

This study was funded by the Taiwan Ministry of Science and Technology (NSC101–3114-Y-002-003, MOST104–2321-B-002-058) and the Ministry of Health and Welfare (MOHW105-CDC-C-114-00103). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Guarantor of the paper JYW.

Availability of data and materials

Details of the computer code for statistical analyses are available from the corresponding author at: jywang@ntu.edu.tw.

Authors’ contributions

LYC drafted the manuscript and designed the study with JYW and CHL. CHL and MCL were involved in data processing. JYW, LYC, CHC, and MRL performed statistical analysis. LNL was the director responsible for general organization and instruction. All authors reviewed, provided input and approved the final manuscript.

Ethics approval and consent to participate

The Institutional Review Board of the National Taiwan University Hospital and its Hsinchu Branch approved the study (NTUH REC: 201,309,064 W; NTUH-HC REC: 105–023-E). Due to the retrospective design, inform consent was deemed unnecessary.

Consent for publication

Written informed consents of the four illustrated cases for publication were obtained.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Internal Medicine, National Taiwan University Hospital, Hsinchu Branch, Hsinchu, Taiwan
(2)
Division of Pulmonary Medicine, Wanfang Hospital, Taipei Medical University, Taipei, Taiwan
(3)
School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
(4)
Department of Pharmacy, New Taipei City Hospital, New Taipei City, Taiwan
(5)
School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan
(6)
Department of Internal Medicine, National Taiwan University Hospital, #7, Chung-Shan South Road, Zhongzheng District, Taipei, 10002, Taiwan
(7)
Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan

References

  1. WHO: Global tuberculosis report 2016. In. Genva, Switzland: WHO Press; 2016.Google Scholar
  2. American Thoracic S, CDC, Infectious Diseases Society of American: Treatment of tuberculosis. MMWR Recomm Rep 2003, 52(RR-11):1–77.Google Scholar
  3. Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology. 2002;35(4):883–9.View ArticlePubMedGoogle Scholar
  4. Wang JY, Liu CH, Hu FC, Chang HC, Liu JL, Chen JM, et al. Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. J Inf Secur. 2011;62(6):448–55.Google Scholar
  5. Wang JY, Lee LN, Yu CJ, Chien YJ, Yang PC, Tami G. Factors influencing time to smear conversion in patients with smear-positive pulmonary tuberculosis. Respirology. 2009;14(7):1012–9.View ArticlePubMedGoogle Scholar
  6. Shu CC, Lee CH, Lee MC, Wang JY, Yu CJ, Lee LN. Hepatotoxicity due to first-line anti-tuberculosis drugs: a five-year experience in a Taiwan medical centre. Int J Tuberc Lung Dis. 2013;17(7):934–9.View ArticlePubMedGoogle Scholar
  7. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935–52.View ArticlePubMedGoogle Scholar
  8. Schmidt M, Sondenaa K, Vetrhus M, Berhane T, Eide GE. Long-term follow-up of a randomized controlled trial of observation versus surgery for acute cholecystitis: non-operative management is an option in some patients. Scand J Gastroenterol. 2011;46(10):1257–62.View ArticlePubMedGoogle Scholar
  9. Wang JY, Lee MC, Shu CC, Lee CH, Lee LN, Chao KM, et al. Optimal duration of anti-TB treatment in patients with diabetes: nine or six months? Chest. 2015;147(2):520–8.View ArticlePubMedGoogle Scholar
  10. Wang JY, Sun HY, Wang JT, Hung CC, Yu MC, Lee CH, et al. Nine- to twelve-month anti-tuberculosis treatment is associated with a lower recurrence rate than 6-9-month treatment in human immunodeficiency virus-infected patients: a retrospective population-based cohort study in Taiwan. PLoS One. 2015;10(12):e0144136.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Mitchell JR, Zimmerman HJ, Ishak KG, Thorgeirsson UP, Timbrell JA, Snodgrass WR, et al. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med. 1976;84(2):181–92.View ArticlePubMedGoogle Scholar
  12. Kimura Y, Takada T, Strasberg SM, Pitt HA, Gouma DJ, Garden OJ, et al. TG13 current terminology, etiology, and epidemiology of acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2013;20(1):8–23.View ArticlePubMedGoogle Scholar
  13. Attili AF, Capocaccia R, Carulli N, Festi D, Roda E, Barbara L, et al. Factors associated with gallstone disease in the MICOL experience. Multicenter Italian study on epidemiology of Cholelithiasis. Hepatology. 1997;26(4):809–18.View ArticlePubMedGoogle Scholar
  14. De Santis A, Attili AF, Ginanni Corradini S, Scafato E, Cantagalli A, De Luca C, et al. Gallstones and diabetes: a case-control study in a free-living population sample. Hepatology. 1997;25(4):787–90.View ArticlePubMedGoogle Scholar
  15. Campbell PT, Newton CC, Patel AV, Jacobs EJ, Gapstur SM. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care. 2012;35(9):1835–44.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Chen JY, Hsu CT, Liu JH, Tung TH. Clinical predictors of incident gallstone disease in a Chinese population in Taipei, Taiwan. BMC Gastroenterol. 2014;14:83.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Festi D, Dormi A, Capodicasa S, Staniscia T, Attili AF, Loria P, et al. Incidence of gallstone disease in Italy: results from a multicenter, population-based Italian study (the MICOL project). World J Gastroenterol. 2008;14(34):5282–9.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2009;32(5):834–8.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Boland LL, Folsom AR, Rosamond WD. Atherosclerosis risk in communities study I: Hyperinsulinemia, dyslipidemia, and obesity as risk factors for hospitalized gallbladder disease. A prospective study. Ann Epidemiol. 2002;12(2):131–40.View ArticlePubMedGoogle Scholar
  20. Halldestam I, Kullman E, Borch K. Incidence of and potential risk factors for gallstone disease in a general population sample. Br J Surg. 2009;96(11):1315–22.View ArticlePubMedGoogle Scholar
  21. Aune D, Vatten LJ. Diabetes mellitus and the risk of gallbladder disease: a systematic review and meta-analysis of prospective studies. J Diabetes Complicat. 2016 Mar;30(2):368–73.View ArticlePubMedGoogle Scholar
  22. Gou XY, Xu XF, Zhang QZ, Li C, Deng Y, Jiang Y, et al. The inhibition of hepatic bile acids transporters Ntcp and Bsep is involved in the pathogenesis of isoniazid/rifampicin-induced hepatotoxicity. Toxicol Mech Methods. 2015;25(5):382–7.View ArticleGoogle Scholar
  23. Kong FM, Sui CY, Li YG, Guo KJ, Guo RX. Hepatobiliary membrane transporters involving in the formation of cholesterol calculus. Hepatobiliary Pancreat Dis Int. 2006 May;5(2):286–9.PubMedGoogle Scholar
  24. Van Erpecum KJ. Pathogenesis of cholesterol and pigment gallstones: an update. Clin Res Hepatol Gastroenterol. 2011;35(4):281–7.View ArticlePubMedGoogle Scholar
  25. Bennion LJ, Grundy SM. Effects of diabetes mellitus on cholesterol metabolism in man. N Engl J Med. 1977;296(24):1365–71.View ArticlePubMedGoogle Scholar
  26. Ponz De Leon M, Ferenderes R, Carulli N. Bile composition in patients with high risk of cholelithiasis. Minerva Med. 1976;67(53):3483–90.PubMedGoogle Scholar
  27. Pazzi P, Scagliarini R, Gamberini S, Pezzoli A. Review article: gall-bladder motor function in diabetes mellitus. Aliment Pharmacol Ther. 2000;14(Suppl 2):62–5.View ArticlePubMedGoogle Scholar
  28. Shaw SJ, Hajnal F, Lebovitz Y, Ralls P, Bauer M, Valenzuela J, et al. Gallbladder dysfunction in diabetes mellitus. Dig Dis Sci. 1993;38(3):490–6.View ArticlePubMedGoogle Scholar
  29. Catnach SM, Ballinger AB, Stevens M, Fairclough PD, Trembath RC, Drury PL, et al. Erythromycin induces supranormal gall bladder contraction in diabetic autonomic neuropathy. Gut. 1993;34(8):1123–7.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Braverman DZ. The lack of effect of metoclopramide on gallbladder volume and contraction in diabetic cholecystoparesis. Am J Gastroenterol. 1986;81(10):960–2.PubMedGoogle Scholar
  31. Mansi C, Savarino V, Vigneri S, Sciaba L, Perilli D, Mele MR, et al. Effect of D2-dopamine receptor antagonist levosulpiride on diabetic cholecystoparesis: a double-blind crossover study. Aliment Pharmacol Ther. 1995;9(2):185–9.View ArticlePubMedGoogle Scholar
  32. Kapicioglu S, Senturk O, Bambul N, Ilgun K. Action of cisapride on gallbladder contraction in patients with diabetes mellitus. Hepato-Gastroenterology. 1998;45(23):1410–4.PubMedGoogle Scholar
  33. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. 2002;123(5):1649–58.View ArticlePubMedGoogle Scholar
  34. Chitturi S, Farrell GC. Drug-induced liver disease. Curr Treat Options Gastroenterol. 2000;3(6):457–62.View ArticlePubMedGoogle Scholar
  35. Capelle P, Dhumeaux D, Mora M, Feldmann G, Berthelot P. Effect of rifampicin on liver function in man. Gut. 1972;13(5):366–71.View ArticlePubMedPubMed CentralGoogle Scholar
  36. TSTLD. Taiwan guidelines for TB diagnosis and treatment. 5.1th ed. Taiwan: TSTLD Press; 2015.Google Scholar

Copyright

Advertisement